Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee. The company’s research has also included locally delivered treatments for gastrointestinal and other inflammatory conditions, including programs designed to address ulcerative colitis and related diseases.

Founded in 2011 and headquartered in Victoria, British Columbia, Eupraxia conducts research and clinical development activities through international collaborations and clinical programs. Its shares trade on the Nasdaq Capital Market under the symbol EPRX.

Key Stats

• Today's Range: $6.70 to $7.61
• 50-Day Range: $6.34 to $9.10
• 52-Week Range: $5.25 to $9.32
• Volume: 348,796 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $446.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.80
• Consensus Rating: Moderate Buy

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

Eupraxia Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 346th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eupraxia Pharmaceuticals has a consensus price target of $17.80, representing about 159.1% upside from its current price of $6.87.

Amount of Analyst Coverage

Eupraxia Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.85) to ($0.99) per share.

Price to Book Value per Share Ratio

Eupraxia Pharmaceuticals has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.46% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 11.07, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 10.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eupraxia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.35

News Sentiment

Eupraxia Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for EPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Eupraxia Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/03/2026
• 2026 Stifel Healthcare Conference: 11/10/2026
• Analyst Day 2026: 11/13/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 49
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Eupraxia Pharmaceuticals: $17.80
• High Price Target: $25.00
• Low Price Target: $11.00
• Potential Upside/Downside: +159.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.97%
• Return on Assets: -43.32%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 16.00
• Quick Ratio: 16.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 4.87

Miscellaneous

• Outstanding Shares: 65,020,000
• Free Float: N/A
• Market Cap: $446.69 million
• Optionable: N/A
• Beta: 0.83